

Amygdala and Hippocampal Volumes in Adolescents and Adults With Bipolar Disorder

Hilary P. Blumberg, MD; Joan Kaufman, PhD; Andrés Martin, MD, MPH; Ronald Whiteman, BA;
Jane Hongyuan Zhang, PhD; John C. Gore, PhD; Dennis S. Charney, MD;
John H. Krystal, MD; Bradley S. Peterson, MD

Background: The purported functions of medial temporal lobe structures suggest their involvement in the pathophysiology of bipolar disorder (BD). Previous reports of abnormalities in the volume of the amygdala and hippocampus in patients with BD have been inconsistent in their findings and limited to adult samples. Appreciation of whether volumetric abnormalities are early features of BD or whether the abnormalities represent neurodegenerative changes associated with illness duration is limited by the paucity of data in juvenile samples.

Objective: To investigate amygdala and hippocampal volume in adults and adolescents with BD.

Setting and Participants: Subjects included 36 individuals (14 adolescents and 22 adults) in outpatient treatment for BD type I at a university hospital or Veterans Affairs medical center or in the surrounding community, and 56 healthy comparison subjects (23 adolescents and 33 adults).

Design and Main Outcome Measures: Amygdala and hippocampal volumes were defined and measured on high-resolution anatomic magnetic resonance imaging scans. We

used a mixed-model, repeated-measures statistical analysis to compare amygdala and hippocampal volumes across groups while covarying for total brain volume, age, and sex. Potential effects of illness features were explored, including rapid cycling, medication, alcohol or other substance dependence, duration, and mood state.

Results: For both the amygdala and hippocampal regions, we found an overall significant volume reduction in the BD compared with the control group ($P < .0001$). Amygdala volume reductions (15.6%) were highly significant ($P < .0001$). We observed a nonsignificant trend ($P = .054$) toward reductions in hippocampal volumes of lesser magnitude (5.3%). Effects of illness features were not detected.

Conclusions: These results suggest that BD is associated with decreased volumes of medial temporal lobe structures, with greater effect sizes in the amygdala than in the hippocampus. These abnormalities are likely manifested early in the course of illness, as they affected adolescent and adult subjects similarly in this sample.

Arch Gen Psychiatry. 2003;60:1201-1208

THE NEUROBIOLOGY of adolescent and adult bipolar disorder (BD) has received little study, although the identification of brain abnormalities associated with early onset and age-related disease progression could help to inform prevention and treatment strategies. Medial temporal lobe abnormalities have been implicated in the pathophysiology of BD by studies of localized lesions, seizure disorders, and neuropsychological test performance. Lesions in this brain region, especially those that produce seizure foci, are associated with episodic symptoms that range from inappropriate elation, grandiosity, distractibility, and hypersexuality to depression, excessive guilt, circumstantiality, and paranoia.¹⁻⁴ Preclinical observation of the

vulnerability of medial temporal structures to sensitization spawned a valuable heuristic model to conceptualize the increased rate of BD cycling as a consequence of the increasing accumulation of multiple, untreated affective episodes.⁵ The reduction of sensitization by anticonvulsants led to their successful implementation in the treatment of BD.^{5,6} In adult BD, the impaired recognition of facial affects and the inappropriate emotional biasing of cognitive functions have implicated disturbances in amygdala functioning.⁷⁻¹⁰ Verbal learning deficits during times of mania and euthymia in adults with BD,¹¹⁻¹³ discordant monozygotic twins, and non-twin siblings^{14,15} implicate a trait deficit in hippocampal functioning.

Functional and structural neuroimaging studies in adult BD further support

Author affiliations are listed at the end of this article.

Table 1. Features of the BD and Healthy Control Groups*

	BD Group (n = 36)	Healthy Control Group (n = 56)	P Value†
Sex			
Male	16 (44)	29 (52)	.49
Female	20 (56)	27 (48)	
Age, mean (SD), y	31.0 (14.1)	28.3 (13.7)	.23
Age group‡			
Adolescent	14 (39)	23 (41)	.83
Adult	22 (61)	33 (59)	
TBV, mean (SD), mm ³	1 165 475 (138 447)	1 195 615 (124 817)	.28

Abbreviations: BD, bipolar disorder; TBV, total brain volume.

*Unless otherwise indicated, data are expressed as number (percentage) of subjects.

†Calculated for comparison between the healthy control and BD groups.

‡For purposes of this study, adults are aged 23 to 57 years; adolescents, 10 to 22 years.

amygdala and hippocampal involvement in the illness. Reports of functional abnormalities in the temporal lobe in adult subjects with BD¹⁶⁻¹⁹ include recent observations of increased amygdala activity in depressed subjects with BD at rest^{20,21} and during performance of a facial emotion recognition task.⁷ Reports of abnormal amygdala volumes in adult BD have been highly variable and include negative findings, increases and decreases in volume, and findings that have been unilateral and bilateral.²²⁻²⁵ Studies of hippocampal volumes in adult BD have also yielded variable findings that include no group differences, as well as unilateral decreases in subjects with BD, and in ill members of monozygotic twin pairs who are discordant for BD.²²⁻²⁸ Data conflict as to whether volume abnormalities in medial temporal lobe structures are present at the time of the first episode or increase in magnitude with the duration of illness.^{23,24,27,29}

We are unaware of previous imaging studies of the anatomic or functional integrity of the amygdala or hippocampus in juveniles with BD. In one study of juvenile BD, clinical interpretation of magnetic resonance imaging scans was suggestive of an increased incidence of abnormal asymmetry of the temporal horn of the lateral ventricles. Amygdala and hippocampal measurements, however, were not reported.³⁰ We report herein a study of amygdala and hippocampal volumes in adolescents and adults with BD compared with healthy control subjects.

METHODS

SUBJECTS

Patients (**Table 1**) included 22 adult outpatients with BD I (aged 23-54 years; 12 [55%] female; 8 [36%] free of medication) treated at the Connecticut Veterans Affairs Medical Center, West Haven, or the Yale University School of Medicine Medical Center, New Haven, Conn, or by practitioners in the community, and 14 adolescent outpatients with BD I (aged 10-22 years; 8 [57%] female; 6 [43%] free of medication) treated at the Yale Child Study Center, New Haven, or in the local community. The control group consisted of 33 healthy adults (aged, 24-57

years; 17 females [52%]) and 23 healthy adolescents (aged 10-22 years; 10 females [43%]).

Healthy adult controls were recruited by word of mouth and advertisement in the surrounding community. Healthy adolescent controls were selected randomly from a list of 10 000 names purchased from a telemarketing company of potential subjects living in the same range of neighborhoods as the patients in an attempt to draw from similar socioeconomic backgrounds. Introductory letters were followed by screening telephone calls. Of the eligible control families contacted, approximately 10% participated. After complete description of the study, written informed consent was provided by all study subjects 18 years and older. For the younger subjects, written informed consent was provided by a guardian and written informed assent was provided by the subject.

Structured clinical interviews confirmed the presence or absence of DSM-IV Axis I disorders. The Structured Clinical Interview for DSM-IV Axis I & II Disorders, Version 2.0,³¹ for the adults was performed by a board-certified adult psychiatrist (H.P.B.), and the revised Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version³² for subjects 18 years and younger (juvenile subjects) was performed by a board-certified child psychiatrist and a psychologist expert in childhood mood disorders (A.M. and J.K., respectively). For the juvenile subjects, interviews were administered separately to the subject and a parent (or maternal grandmother for 1 patient). Final DSM-IV diagnoses were established by the consensus diagnosis of clinical and structured interviews. All patients met criteria for BD I. All patients also reported at least 1 first- or second-degree relative with a mood-spectrum disorder that included BD, major depressive disorder, or alcohol abuse, although a positive family history was not required for study entry.

Nine adults and 7 adolescents (44% of the patients) met criteria for rapid cycling (this and other clinical features are summarized in **Table 2**). Eleven (31%) of the BD subjects had a history of alcohol dependence (9 adults and 2 adolescents). History of dependence or abuse of other substances included marijuana abuse/dependence (8 adults and 3 adolescents [31%]), cocaine dependence (2 adults), polysubstance dependence (1 adult), stimulant abuse (1 adult), and hallucinogen abuse (1 adult). Duration of alcohol and substance dependence remission was longer than 5 years, with the exception of 2 subjects who were in remission for only 1 year. Other comorbidities were present only in the adolescents and included 2 subjects each with attention-deficit/hyperactivity disorder, oppositional defiant disorder, and a learning disorder not otherwise specified, and 1 subject each with posttraumatic stress disorder, obsessive-compulsive disorder, avoidant disorder of childhood, and developmental coordination disorder. At the time of scanning, 10 adults (45%) were euthymic, 7 (32%) were in a manic/mixed or hypomanic state, and 5 (23%) were depressed. All adolescents were symptomatic at the time of scanning and reported varying degrees of depressive and manic symptoms consistent with the characteristic clinical presentation in adolescents with BD.³³⁻³⁶ One adolescent had mood symptoms but did not meet DSM-IV criteria for an acute mood episode.

According to the retrospective reporting by BD subjects or by the guardians of juvenile subjects, mean ± SD age of illness onset was 17.4 ± 8.0 years, and mean ± SD illness duration was 13.1 ± 9.5 years. Twenty-two (61%) of all BD subjects had a history of psychiatric hospitalization. Nine adults and 2 adolescents had had 1 hospitalization; 4 adults and 2 adolescents, 2 to 4 hospitalizations; and 4 adults and 1 adolescent, more than 5 hospitalizations.

All subjects had no history of other neurological disorders, loss of consciousness for longer than 5 minutes, or significant medical illness, with the exception of 1 subject each

in the adult and the adolescent BD samples with hypothyroidism. Healthy controls had no history of Axis I disorder in themselves or their first-degree family members. No subject drank alcohol or used street drugs for a minimum of 24 hours before scanning. Medications used by BD subjects included lithium carbonate in 7 adults (32%) and 3 adolescents (21%), anticonvulsants in 7 adults (32%) and 5 adolescents (36%), antidepressants in 10 adults (45%) and 3 adolescents (21%), antipsychotics in 3 adults (14%) and 2 adolescents (14%), benzodiazepines in 1 adult (5%), stimulants in 1 adolescent (7%), clonidine hydrochloride in 1 adolescent (7%), and levothyroxine sodium (Synthroid) in 1 adult (5%) and 1 adolescent (7%).

MAGNETIC RESONANCE IMAGE ACQUISITION AND PROCESSING

Magnetic resonance imaging scans were obtained using a single 1.5-T scanner (GE Signa; General Electric, Milwaukee, Wis). Head positioning was standardized using canthomeatal landmarks. Images were obtained using a 3-dimensional sagittal spoiled gradient echo sequence (repetition time, 24 milliseconds; echo time, 5 milliseconds; flip angle, 45°; frequency encoding superior/inferior; no wrap; 256 × 192 matrix; field of view, 30 cm; 2 excitations; slice thickness, 1.2 mm; and 124 contiguous slices).

Morphometric analyses were performed on Sun Ultra 10 workstations using ANALYZE 7.5 software (Biomedical Imaging Resource, Mayo Foundation, Rochester, Minn) by operators blinded to subject characteristics and hemisphere (images were flipped in the transverse plane randomly before region definition). Large-scale variations in image intensity were removed, and images were reformatted to standardized head flexion/extension, rotation, and tilt using the anterior commissure-posterior commissure and standard midline landmarks. An isointensity contour function was used in conjunction with manual editing to isolate the cerebrum. Total brain volume measures (TBV) (cerebral gray and white matter volume excluding cerebrospinal fluid) were used as covariates in the statistical analyses to control for general scaling effects. In addition, data were analyzed separately using intracranial volume measures (cerebral volume including sulcal cerebrospinal fluid) as covariates in place of TBV to minimize potential effects of atrophy due to neurodegenerative processes.³⁷ The amygdala and hippocampus were defined by means of manual tracing. Initial tracings in the coronal plane were confirmed in orthogonal views. If corrections were made, their accuracy was corroborated in the orthogonal imaging planes. Amygdala and hippocampal delineations were performed in accordance with methods described previously.^{37,38}

Interrater intraclass reliability coefficients, assessed on 10 scans obtained at times spaced equally throughout the study, were 0.89 for amygdala delineations and 0.94 for hippocampal delineations. An expert in these procedures (B.S.P.) reviewed all of the tracings used for this study for spatial accuracy. Spatial agreement for these procedures are approximately 75%.³⁸ Differences in spatial agreement were resolved by the consensus of 2 trained investigators expert in the delineations (R.W. and B.S.P.).

STATISTICAL ANALYSES

We performed all statistics analyses using SAS software, version 8.2 (SAS Institute Inc, Cary, NC). A *P* value of .05 (2-sided) was used as the level of significance for all tests.

Primary Hypothesis Testing

The primary statistical model tested whether the BD and healthy control groups differed in regional volume. The model in-

Table 2. Clinical Features of the BD Group*

	All With BD (n = 36)	Adolescents With BD (n = 14)	Adults With BD (n = 22)
Rapid cycling			
Yes	16 (44)	7 (50)	9 (41)
No	20 (56)	7 (50)	13 (59)
Medication at scan			
Yes	22 (61)	8 (57)	14 (64)
No	14 (39)	6 (43)	8 (36)
Lithium carbonate at scan			
Yes	10 (28)	3 (21)	7 (32)
No	26 (72)	11 (79)	15 (68)
Anticonvulsant at scan			
Yes	12 (33)	5 (36)	7 (32)
No	24 (67)	9 (64)	15 (68)
Antidepressant at scan			
Yes	13 (36)	3 (21)	10 (45)
No	23 (64)	11 (79)	12 (55)
History of alcohol dependence			
Yes	11 (31)	2 (14)	9 (41)
No	25 (69)	12 (86)	13 (59)
History of marijuana abuse/dependence			
Yes	11 (31)	3 (21)	8 (36)
No	25 (69)	11 (79)	14 (64)
Illness duration, mean (SD), y	13.1 (9.5)	5.4 (3.1)	18.0 (9.0)
Age at first episode, mean (SD), y	17.4 (8.0)	10.1 (4.0)	22.1 (6.2)
Mean (SD) No. of hospitalizations	1.9 (2.7)	1.1 (2.0)	2.5 (3.0)
Mood state at scan†			
Euthymic			10 (45)
Elevated			7 (32)
Depressed			5 (23)

Abbreviation: BD, bipolar disorder.


*Unless otherwise indicated, data are expressed as number (percentage) of patients.

†Adolescents with BD had varying degrees of mixed symptoms.

cluded data from all subjects (N=92), 1 fixed effect of diagnosis (BD and healthy), and random subject effects. Repeated measures were performed over the spatial domain for region (amygdala and hippocampus) and hemisphere (right and left). Age group, sex, and TBV served as covariates, and potential 2-, 3-, and 4-way interactions were examined. Terms that were not significant (*P* > .05) were eliminated via backward stepwise regression, with the constraint that the model at each step had to be hierarchically well formulated.³⁹ Data adhered to a normal distribution as assessed by means of the Kolmogorov-Smirnov test. Least squares means, SEs, and 95% confidence intervals were calculated in the mixed model for regional volumes and plotted to interpret diagnosis effects.

Exploration of Associations With Illness Features

Exploratory analyses were performed for potential main effects of clinical variables within the BD group on amygdala or hippocampal volumes by adding the clinical feature covariates to a linear mixed model and then eliminating nonsignificant terms via backward stepwise regression. Main effects examined were presence or absence of rapid cycling, medication status at the time of scanning (present or absent overall, and separately for the presence of lithium, anticonvulsants, or antidepressants at the time of scanning), history of alcohol dependence, and marijuana abuse/dependence. Additional



Amygdala and hippocampal least squares mean volume values and 95% confidence intervals for the bipolar disorder (BD) ($n=36$) and healthy control groups ($n=56$). Means are adjusted for age, sex, and total brain volume. The effect of diagnosis was significant at $P<.0001$.

Table 3. Summary of Least Squares Mean Volumes*

Factors	Least Squares Mean Volume (SE)	P Value†
Diagnosis		
Healthy controls	2672 (34)] <.0001
BD	2420 (43)	
Sex		
F	2457 (40)] .004
M	2637 (42)	
Hemisphere		
Left	2562 (28)] .04
Right	2532 (28)	
Region		
Amygdala	1970 (32)] <.0001
Hippocampus	3124 (44)	
Region, diagnosis		
Amygdala, control	2137 (40)] .001
Amygdala, BD	1803 (49)	
Hippocampus, control	3209 (54)] .054
Hippocampus, BD	3039 (68)	
Region, age group, diagnosis		
Amygdala, adolescent control	2169 (81)] .001
Amygdala, adolescent BD	1834 (93)	
Amygdala, adult control	2117 (60)] <.0001
Amygdala, adult BD	1780 (75)	
Hippocampus, adolescent control	3235 (100)] .049
Hippocampus, adolescent BD	2955 (120)	
Hippocampus, adult control	3191 (78)] .40
Hippocampus, adult BD	3090 (96)	

Abbreviation: BD, bipolar disorder.

*Mean volumes were adjusted for age, sex, hemisphere, region, and total brain volume. For purposes of this study, adults are aged 23 to 57 years; adolescents, 10 to 22 years.

†Calculated for the comparisons between the bracketed groups.

covariates were duration of illness, age at first episode, and number of hospitalizations. Interaction terms were not included because of the number of covariates explored compared with the number of subjects. Mood state was explored for the 22 adults with BD only using a similar mixed model. Analyses of mood state were not performed for the juvenile sample as, for the most part, they presented with varying degrees of mixed symptoms.

RESULTS

The BD and control groups did not differ significantly in age overall (Table 1), or between the adult (mean \pm SD ages of healthy vs BD adults, 37.8 ± 9.4 vs 40.7 ± 8.0 years; $P=.23$) or adolescent (mean \pm SD ages of healthy vs BD adolescents, 14.4 ± 3.5 vs 15.7 ± 4.0 years; $P=.29$) subgroups.

PRIMARY ANALYSES

The main effect of overall diagnosis was significant ($F_{1,88}=21.02$; $P<.0001$). The diagnosis \times region interaction approached significance ($F_{1,89}=3.35$; $P=.07$). None of the other 2- and 3-way interactions of region, hemisphere, sex, and age with diagnosis was significant ($P>.10$). A significant effect of TBV ($F_{1,88}=8.52$; $P=.004$) indicated that general scaling within the brain accounted for some of the variance in regional volume. Amygdala and hippocampal volumes were smaller in female than in male subjects ($F_{1,87}=8.55$; $P=.004$) and larger in the left than in the right hemisphere ($F_{1,91}=4.41$; $P=.04$).

The difference of least squares means between the diagnostic groups (Figure and Table 3) indicated that the stronger contribution to group differences was mainly derived from smaller bilateral amygdala volumes in the BD group compared with the healthy control group. Amygdala and hippocampal volumes were also evaluated individually, with Bonferroni correction for multiple comparisons with an overall type I error of .05. Amygdala volumes were decreased significantly in the BD group compared with the healthy control group by 15.6% ($P<.0001$). Hippocampal volumes were decreased to a lesser extent, 5.3%, that approached but did not reach significance ($P=.054$). Group least squares means were calculated for age subgroups and support a consistent diagnosis trend across age groups. Use of intracranial volume as a covariate in the analyses yielded similar results to analyses that used TBV (intracranial volume and TBV correlation, $r=0.97$).

EXPLORATORY ANALYSES

No significant main effects of illness features on regional volumes in BD were detected; however, this part of analysis is very preliminary given the number of covariates explored in relation to the sample size.

COMMENT

We found bilateral decreases in volumes of the amygdala in individuals with BD compared with healthy controls. Reduced volumes were observed in adolescent and adult samples, and age did not affect group comparisons. A nonsignificant trend toward decreases in volumes of the hippocampus bilaterally in BD subjects was also observed, although the magnitude of these volume reductions was much less prominent than in the amygdala.

The reduced volumes detected in this study could be a consequence of a number of different cellular pro-

cesses, including loss or atrophy of neurons or glia, an altered ratio of small to large cell types, or a decreased density of neuronal processes.⁴⁰ The limited available data on the cytoarchitectonic features of the amygdala and hippocampus in BD subjects provide suggestive, but not conclusive, evidence of the presence of cellular abnormalities. One study, for example, reported decreased glial cell density in the amygdala of BD subjects,⁴¹ whereas neuronal abnormalities have not yet been reported, to our knowledge. Studies of the cytoarchitecture of the hippocampus in BD are more numerous and suggest the presence of aberrant neurodevelopment and synaptic remodeling in the illness.⁴²⁻⁴⁹

Cellular and synaptic disturbances in the amygdala and hippocampus in BD could represent primary abnormalities in these structures, interactions between the structures (such as influences on the hippocampus from a more central abnormality of the amygdala), or consequences of primary abnormalities in other regions with which the amygdala and hippocampus are connected. A more central abnormality in the amygdala is suggested by the larger reductions in volume of the amygdala than of the hippocampus that were detected herein, as well as by previous imaging findings of excessive amygdala activity in BD subjects.^{20,21} In addition, preclinical studies have shown that excessive activity of the amygdala produces synaptic changes in the hippocampus that are similar to those observed in BD subjects in postmortem studies.^{45,47,50-52} The possibility of excessive glutamatergic input to the amygdala from the frontal cortices is suggested by findings in subjects with BD of hyperactivity in paralimbic cortices, which are densely interconnected with the amygdala and hippocampus, as well as by abnormalities in glutamate receptors within the medial temporal lobe.^{49,52-56}

Greater differences in hippocampal volume between the BD and healthy control groups were observed in the adolescent subgroup than in the adult subgroup. Thus, our findings do not support the presence of excessive degeneration of the hippocampus with age in subjects with BD, and presumably with increasing accumulation of stressful life experiences, a pathological process postulated in major depressive disorder.⁵⁷⁻⁵⁹ Our findings do not, however, contradict a potentially significant role for glucocorticoids in earlier developmental periods than those studied herein, and do not conflict with a role for glucocorticoids in the modulation of medial temporal function in already abnormal structures.

Potential behavioral consequences of amygdala and hippocampal abnormalities include deficits in adaptive responses to emotionally relevant stimuli in subjects with BD.⁶⁰⁻⁶⁶ Similar to individuals with amygdala lesions,⁶⁵ individuals with BD are impaired in their ability to recognize fearful faces,⁷⁻⁹ and preliminary evidence suggests that this deficit is associated with abnormal amygdala activity in response to the viewing of the fearful faces.⁷ Volumetric abnormalities in the hippocampus have been suggested to contribute to cognitive impairments, such as deficits in verbal learning, that have been reported in BD subjects.^{28,67,68} The dense connections of structures in the medial temporal lobe with the frontal cortices and the brainstem tegmentum, hypothalamus, and autonomic nuclei suggest that cognitive and neurovegeta-

tive functions may also be affected by amygdala and hippocampal abnormalities.^{56,61,69}

Volume abnormalities of the amygdala and hippocampus support consideration of these regions as potential pharmacological targets in the treatment of BD. Excessive activity in the amygdala and in cortical regions connected with the amygdala normalize during recovery from depression in individuals with BD who are taking mood-stabilizing medications.^{20,70} Abnormalities reported in the γ -aminobutyric acid, glutamate, serotonin, and opiate systems within the amygdala and hippocampus of BD subjects^{43,49,71-73} suggest potential pharmacological targets in developing new treatments for this illness.

Our findings are consistent with several previous reports of decreased amygdala and hippocampal volume in adult BD, although those findings tended to be unilateral.^{22,25,27} Previous observations of abnormalities in the volumes of the amygdala and hippocampus in patients with first-episode BD or affective psychoses^{23,27} support the presence of abnormalities in these structures early in the course of illness. Previous findings in BD, however, also include increased volumes or absences of significant group differences, compared with normal controls.²²⁻²⁶ Salient methodological differences in our study compared with previous studies may include increased signal to noise accomplished with 2 excitations used during image acquisition and the methods used to delineate amygdala and hippocampal volumes. The choice of the anterior commissure–posterior commissure plane as the reference plane for positional normalization,^{25,38,74-78} compared with the plane perpendicular to the long axis of the hippocampus,^{11,24,78-82} is thought to increase the reliability of amygdala volume measurements and thus may be optimal for studies focused on the amygdala.³⁸ Delineations included the full extent of the amygdala and hippocampus, and boundaries were confirmed in multiple viewing planes, which is thought to increase the reliability of volume measurements.^{38,76,83,84} Other groups vary in the relative inclusion of transitional structures and surrounding cortex, or in the viewing planes used for delineations.^{11,24,25,78-89} Use of TBV to covary for scaling effects, as performed in this study, may represent a salient difference from other studies. For example, temporal lobe volumes have also been used to correct for scaling effects within the brain,²⁴ but have been reported to be abnormal in BD,^{25,90} and could confound interpretation of group differences in amygdala volumes.

We did not detect significant effects of age, rapid cycling, the presence of medications, illness duration, or mood state; however, our ability to detect effects of these factors could have been limited by inadequate power. Furthermore, different characteristics in the BD subject samples of other studies may have contributed to the different results across centers. For example, samples studied by other groups included higher proportions of male subjects or older subjects,^{23,24} subjects with a history of psychosis, or subjects in primarily euthymic²⁴ or manic/mixed mood states.²³ Differences in medications in other studies may include higher proportions of subjects receiving lithium at the time of scanning and with a lifetime history of exposure to antipsychotic medication.^{23,24} Effects of individual medications may be revealed

by systematic study of specific agents. We also did not detect effects of the history of alcohol or marijuana dependence. However, features such as the duration of use of specific medications or features of alcohol history (eg, the number of withdrawals or the duration of alcohol abuse)⁹¹ may in future work be found to contribute significantly to volume abnormalities in BD, as has been found in other disorders. Individuals with other comorbid diagnoses were not present in sufficient numbers to permit systematic analyses; however, reports of structural abnormalities in association with diagnoses such as attention-deficit/hyperactivity disorder suggest that comorbidities have the potential to effect the data.^{88,92}

The ability to generalize from this patient sample is limited. This was a cross-sectional study. The patients in the 2 age groups might have had different pathophysiological subtypes of the disorder or different illness course features that could have affected the findings. Longitudinal study of the adolescents sampled herein might reveal changes with age in the morphologic characteristics of the amygdala or hippocampus not detected in the adults sampled. The selection of subjects was biased toward individuals who could tolerate the scanning procedure. The patient sample was further constrained to minimize the confounding effects of active comorbid substance abuse on regional volumes, although comorbid substance abuse is frequently seen in clinical BD populations.^{39,93,94} Furthermore, rates of other comorbid diagnoses such as attention-deficit/hyperactivity disorder were relatively low, as patients were excluded from the study if there was a question of whether their symptoms could be accounted for by another diagnosis.

CONCLUSIONS

This study provides preliminary evidence of structural abnormalities in the amygdala and hippocampus common to adolescent and adult BD. These common abnormalities may represent the expression of a common genetic vulnerability to BD, or they might represent biological consequences of earlier features of the illness. Studies of prepubescent samples, longitudinal investigations, and studies of family members may in the future help to identify phenotypes associated with a genetic risk for BD and help to elucidate the neurodevelopmental correlates of BD.

Submitted for publication June 28, 2002; final revision received March 5, 2003; accepted April 11, 2003.

From the Departments of Psychiatry (Drs Blumberg, Kaufman, and Krystal) and Diagnostic Radiology (Dr Gore), and the Yale Child Study Center (Dr Martin), Yale University School of Medicine, New Haven, Conn; the Department of Psychiatry, Veterans Affairs Connecticut Healthcare System (Drs Blumberg and Krystal), and the Department of Veterans Affairs Cooperative Studies Program Coordinating Center (Dr Zhang), West Haven, Conn; the Department of Psychiatry, Columbia College of Physicians and Surgeons (Mr Whiteman and Dr Peterson), and the New York State Psychiatric Institute (Dr Peterson), New York; the Mood and Anxiety Disorders Research Program, National Institute of Mental Health, Bethesda, Md (Dr Charney); and the

Department of Radiology, Vanderbilt University Medical Center, Nashville, Tenn (Dr Gore).

This study was supported by research grants from The Stanley Medical Research Institute (Bethesda, Md) (Dr Blumberg), National Alliance for Research in Affective Disorders and Schizophrenia (Great Neck, NY) (Dr Blumberg), The Ethel F. Donaghue Women's Investigator Program at Yale (New Haven, Conn) (Dr Blumberg), and Charles A. Dana Foundation (New York, NY) (Dr Peterson); the Suzanne Crosby Murphy Endowment at Columbia University College of Physicians and Surgeons (New York) (Dr Peterson); the Department of Veterans Affairs (Washington, DC) Research Career Development award (Dr Blumberg), Merit Review award (Dr Blumberg), Research Enhancement Award Program (Drs Blumberg and Krystal), Alcohol Research Center (Dr Krystal) and Clinical Neurosciences Division of the National Center for PTSD (Drs Kaufman and Krystal); and the National Institute of Mental Health Mental Health Clinical Research Center (Bethesda) (Drs Blumberg, Charney, and Krystal); MH01232 (Dr Peterson), MH59139 (Dr Peterson), MH01792 (Dr Martin), and grant KO2AA 00261-01 from the National Institute on Alcohol Abuse and Alcoholism (Bethesda) (Dr Krystal).

We thank Kathleen Colonese, BA, for her expert care in coordinating the research; Ralitzia Gueorguieva, PhD, for her statistical consultation; Amy Basile, BA, Magdi Tageldin, MD, and Michael Kane, BA, for their assistance with morphometry; Heather Douglas-Palumberi, MA, and Mindy Crouse-Artus, MA, for their assistance with the adolescents; Cheryl Lacadie, BS, Hedy Sarofin, RTRMR, and Terry Hickey, RTRMRN, for their technical expertise; and the research subjects for their participation.

Corresponding author and reprints: Hilary P. Blumberg, MD, Department of Psychiatry 116a, Veterans Affairs Connecticut Healthcare System, 950 Campbell Ave, West Haven, CT 06516 (e-mail: hilary.blumberg@yale.edu).

REFERENCES

1. Flor-Henry P. Schizophrenia-like reactions and affective psychoses associated with temporal lobe epilepsy: etiological factors. *Am J Psychiatry*. 1969;126:400-404.
2. Bear DM, Fedio P. Quantitative analysis of interictal behavior in temporal lobe epilepsy. *Arch Neurol*. 1977;34:454-467.
3. Shukla S, Cook BL, Mukherjee S, Godwin C, Miller MG. Mania following head trauma. *Am J Psychiatry*. 1987;144:93-96.
4. Starkstein SE, Boston JD, Robinson RG. Mechanisms of mania after brain injury: 12 case reports and review of the literature. *J Nerv Ment Dis*. 1988;176:87-100.
5. Post RM, Uhde TW, Putnam FW, Ballenger JC, Berrettini WH. Kindling and carbamazepine in affective illness. *J Nerv Ment Dis*. 1982;170:717-731.
6. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder (revision). *Am J Psychiatry*. 2002;159(4, suppl):1-50.
7. Yurgelun-Todd DA, Gruber SA, Kanayama G, Killgore WD, Baird AA, Young AD. fMRI during affect discrimination in bipolar affective disorder. *Bipolar Disord*. 2000;2:237-248.
8. George MS, Huggins T, McDermut W, Parekh PI, Rubinow D, Post RM. Abnormal facial emotion recognition in depression: serial testing in an ultra-rapid-cycling patient. *Behav Modif*. 1998;22:192-204.
9. Lembke A, Ketter TA. Impaired recognition of facial emotion in mania. *Am J Psychiatry*. 2002;159:302-304.
10. Murphy FC, Sahakian BJ, Rubinsztein JS, Michael A, Rogers RD, Robbins TW, Paykel ES. Emotional bias and inhibitory control processes in mania and depression. *Psychol Med*. 1999;29:1307-1321.
11. Van Gorp WG, Altshuler L, Theberge DC, Mintz J. Declarative and procedural memory in bipolar disorder. *Biol Psychiatry*. 1999;46:525-531.

12. Clark L, Iversen SD, Goodwin GM. A neuropsychological investigation of prefrontal involvement in acute mania. *Am J Psychiatry*. 2001;158:1605-1611.
13. Wolfe J, Granholm E, Butters N, Saunders E, Janowsky D. Verbal memory deficits associated with major affective disorders: a comparison of unipolar and bipolar patients. *J Affect Disord*. 1987;13:83-92.
14. Keri S, Kelemen O, Benedek G, Janka Z. Different trait markers for schizophrenia and bipolar disorder: a neurocognitive approach. *Psychol Med*. 2001;31:915-922.
15. Gourovitch ML, Torrey EF, Gold JM, Randolph C, Weinberger DR, Goldberg TE. Neuropsychological performance of monozygotic twins discordant for bipolar disorder. *Biol Psychiatry*. 1999;45:639-646.
16. Migliorelli R, Starkstein SE, Teson A, de Quiros G, Vazquez S, Leiguarda R, Robinson RG. SPECT findings in patients with primary mania. *J Neuropsychiatry Clin Neurosci*. 1993;5:379-383.
17. O'Connell RA, Van Heertum RL, Luck D, Yudd AP, Cueva JE, Billick SB, Cordon DJ, Gersh RJ, Masdeu JC. Single-photon emission computed tomography of the brain in acute mania and schizophrenia. *J Neuroimaging*. 1995;5:101-104.
18. Gyulai L, Alavi A, Broich K, Reilly J, Ball WB, Whybrow PC. I-123 Iofetamine single-photon emission tomography in rapid cycling bipolar disorder: a clinical study. *Biol Psychiatry*. 1997;41:152-161.
19. Post RM, DeLisi LE, Holcomb HH, Uhde TW, Cohen R, Buchsbaum MS. Glucose utilization in the temporal cortex of affectively ill patients: positron emission tomography. *Biol Psychiatry*. 1987;22:545-553.
20. Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. *Pharmacol Biochem Behav*. 2002;71:431-447.
21. Ketter TA, Kimbrell TA, George MS, Dunn RT, Speer AM, Benson BE, Willis MW, Danielson A, Frye MA, Herscovitch P, Post RM. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. *Biol Psychiatry*. 2001;49:97-109.
22. Swayze VW II, Andreasen NC, Alliger RJ, Yuh WTC, Ehrhardt JC. Subcortical and temporal structures in affective disorders and schizophrenia: a magnetic resonance imaging study. *Biol Psychiatry*. 1992;31:221-240.
23. Strakowski SM, DeBello MP, Sax KW, Zimmerman ME, Shear PK, Hawkins JM, Larson ER. Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. *Arch Gen Psychiatry*. 1999;56:254-260.
24. Altshuler LL, Bartzokis G, Grieder T, Curran J, Jimenez T, Leight K, Wilkins J, Gerner R, Mintz J. An MRI study of temporal lobe structures in men with bipolar disorder or schizophrenia. *Biol Psychiatry*. 2000;48:147-162.
25. Pearlson GD, Barta PE, Powers RE, Menon RR, Richards SS, Aylward EH, Fiederman EB, Chase GA, Petty RG, Tien AY. Medial and superior temporal gyral volumes and cerebral asymmetry in schizophrenia versus bipolar disorder. *Biol Psychiatry*. 1997;41:1-14.
26. Hauser P, Matochik J, Altshuler LL, Denicoff KD, Conrad A, Li X, Post RM. MRI-based measurements of temporal lobe and ventricular structures in patients with bipolar I and bipolar II disorders. *J Affect Disord*. 2000;60:25-32.
27. Velakoulis D, Pantelis C, McGorry PD, Dudgeon P, Brewer W, Cook M, Desmond P, Bridle N, Tierney P, Murrin V, Singh B, Copolov D. Hippocampal volume in first-episode psychoses and chronic schizophrenia. *Arch Gen Psychiatry*. 1999;56:133-141.
28. Noga JT, Vladar K, Torrey EF. A volumetric magnetic resonance imaging study of monozygotic twins discordant for bipolar disorder. *Psychiatry Res*. 2001;106:25-34.
29. Ali SO, Denicoff KD, Altshuler LL, Hauser P, Li X, Conrad AJ, Smith-Jackson EE, Leverich GS, Post RM. Relationship between prior course of illness and neuroanatomic structures in bipolar disorder: a preliminary study. *Neuropsychiatry Neuropsychol Behav Neurol*. 2001;14:227-232.
30. Botteron KN, Vannier MW, Geller B, Todd RD, Lee BCP. Preliminary study of magnetic resonance imaging characteristics in 8- to 16-year-olds with mania. *J Am Acad Child Adolesc Psychiatry*. 1995;34:742-749.
31. First MB, Spitzer RL, Gibbon M, Williams JBW. *Structured Clinical Interview for DSM-IV Axis I & II Disorders (Version 2.0)*. New York: New York State Psychiatric Institute; 1995.
32. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version (K-SADS-PL): initial reliability and validity. *J Am Acad Child Adolesc Psychiatry*. 1997;36:980-988.
33. Geller B, Luby J. Child and adolescent bipolar disorder: a review of the past 10 years. *J Am Acad Child Adolesc Psychiatry*. 1997;36:1168-1176.
34. Carlson GA, Bromet EJ, Sievers S. Phenomenology and outcome of subjects with early- and adult-onset psychotic mania. *Am J Psychiatry*. 2000;157:213-219.
35. Biederman J, Mick E, Faraone SV, Spencer T, Wilens TE, Wozniak J. Pediatric mania: a developmental subtype of bipolar disorder? *Biol Psychiatry*. 2000;48:458-466.
36. McElroy SL, Strakowski SM, West SA, Keck PE Jr, McConville BJ. Phenomenology of adolescent and adult mania in hospitalized patients with bipolar disorder. *Am J Psychiatry*. 1997;154:44-49.
37. Peterson BS, Staib L, Scahill L, Zhang H, Anderson C, Leckman JF, Cohen DJ, Gore JC, Albert J, Webster R. Regional brain and ventricular volumes in Tourette syndrome. *Arch Gen Psychiatry*. 2001;58:427-440.
38. Kates WR, Abrams MT, Kaufmann WE, Breiter S, Reiss AL. Reliability and validity of MRI measurement of the amygdala and hippocampus in children with fragile X syndrome. *Psychiatry Res*. 1997;75:31-48.
39. Morrell CH, Pearson JD, Brant LJ. Linear transformations of linear mixed-effects models. *Am Stat*. 1997;51:338-343.
40. Rajkowska G. Cell pathology in mood disorders. *Semin Clin Neuropsychiatry*. 2002;7:281-292.
41. Bowley MP, Drevets WC, Öngür D, Price JL. Low glial numbers in the amygdala in major depressive disorder. *Biol Psychiatry*. 2002;52:404-412.
42. Fatemi SH, Earle JA, McMenomy T. Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. *Mol Psychiatry*. 2000;5:654-663.
43. Benes FM, Kwok EW, Vincent SL, Todtenkopf MS. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. *Biol Psychiatry*. 1998;44:88-97.
44. Vawter MP, Freed WJ, Kleinman JE. Neuropathology of bipolar disorder. *Biol Psychiatry*. 2000;48:486-504.
45. Rosoklija G, Toomayan G, Ellis SP, Keil J, Mann JJ, Latov N, Hays AP, Dwork AJ. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. *Arch Gen Psychiatry*. 2000;57:349-356.
46. Dowlshahi D, MacQueen G, Wang JF, Chen B, Young LT. Increased hippocampal supragranular Timm staining in subjects with bipolar disorder. *Neuroreport*. 2000;11:3775-3778.
47. Fatemi SH, Earle JA, Stary JM, Lee S, Sedgewick J. Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia. *Neuroreport*. 2001;12:3257-3262.
48. Eastwood SL, Harrison PJ. Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: a study of complexin mRNAs. *Mol Psychiatry*. 2000;5:425-432.
49. Law AJ, Deakin JFW. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. *Neuroreport*. 2001;12:2971-2974.
50. Berretta S, Munno DW, Benes FM. Amygdalar activation alters the hippocampal GABA system: "partial" modelling for postmortem changes in schizophrenia. *J Comp Neurol*. 2001;431:129-138.
51. Sutula T, He XX, Cavazos J, Scott G. Synaptic reorganization in the hippocampus induced by abnormal functional activity. *Science*. 1988;239:1147-1150.
52. Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. *Ann N Y Acad Sci*. 1999;877:614-637.
53. Blumberg HP, Stern E, Martinez D, Ricketts S, de Asis J, White T, Epstein J, McBride PA, Eidelberg D, Kocsis JH, Silbersweig DA. Increased anterior cingulate and caudate activity in bipolar mania. *Biol Psychiatry*. 2000;48:1045-1052.
54. Blumberg HP, Leung HC, Skudlarski P, Lacadie CM, Fredericks CA, Harris BC, Charney DS, Gore JC, Krystal JH, Peterson BS. A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. *Arch Gen Psychiatry*. 2003;60:601-609.
55. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. *Mol Psychiatry*. 2002;7(suppl 1):S71-S80.
56. Amaral DG, Price JL. Amygdalo-cortical projections in the monkey (*Macaca fascicularis*). *J Comp Neurol*. 1984;230:465-496.
57. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. *Arch Gen Psychiatry*. 2000;57:925-935.
58. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. *Arch Gen Psychiatry*. 1997;54:597-606.
59. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. *J Neurosci*. 1999;19:5034-5043.
60. Bechara A, Damasio H, Damasio AR, Lee GP. Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. *J Neurosci*. 1999;19:5473-5481.
61. Amaral DG. The primate amygdala and the neurobiology of social behavior: implications for understanding social anxiety. *Biol Psychiatry*. 2002;51:11-17.
62. Davis M, Whalen PJ. The amygdala: vigilance and emotion. *Mol Psychiatry*. 2001;6:13-34.
63. Morris JS, Frith CD, Perrett DI, Rowland D, Young AW, Calder AJ, Dolan RJ. A differential neural response in the human amygdala to fearful and happy facial expressions. *Nature*. 1996;383:812-815.
64. Anderson AK, Phelps EA. Expression without recognition: contributions of the human amygdala to emotional communication. *Psychol Sci*. 2000;11:106-111.

65. Adolphs R, Tranel D, Damasio AR. The human amygdala in social judgment. *Nature*. 1998;393:470-474.
66. Fudge JL, Powers JM, Haber SN, Caine ED. Considering the role of the amygdala in psychotic illness: a clinicopathological correlation. *J Neuropsychiatry Clin Neurosci*. 1998;10:383-394.
67. Sax KW, Strakowski SM, Zimmerman ME, DelBello MP, Keck PE Jr, Hawkins JM. Frontosubcortical neuroanatomy and the continuous performance test in mania. *Am J Psychiatry*. 1999;156:139-141.
68. Ali SO, Denicoff KD, Altshuler LL, Hauser P, Li X, Conrad AJ, Mirsky AF, Smith-Jackson EE, Post RM. A preliminary study of the relation of neuropsychological performance to neuroanatomic structures in bipolar disorder. *Neuropsychiatry Neuropsychol Behav Neurol*. 2000;13:20-28.
69. LeDoux JE, Iwata J, Cicchetti P, Reis DJ. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. *J Neurosci*. 1988;8:2517-2529.
70. Ketter TA, Kimbrell TA, George MS, Willis MW, Benson BE, Danielson A, Frye MA, Herscovitch P, Post RM. Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders. *Biol Psychiatry*. 1999;46:1364-1374.
71. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, Huang Y, Gautier C, Mathis C. PET imaging of serotonin 1A receptor binding in depression. *Biol Psychiatry*. 1999;46:1375-1387.
72. Hurd YL. Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. *Mol Psychiatry*. 2002;7:75-81.
73. Heckers S, Stone D, Walsh J, Shick J, Koul P, Benes FM. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. *Arch Gen Psychiatry*. 2002;59:521-529.
74. Jacobsen LK, Giedd JN, Vaituzis AC, Hamburger SD, Rajapakse JC, Frazier JA, Kaysen D, Lenane MC, McKenna K, Gordon CT, Rapoport JL. Temporal lobe morphology in childhood-onset schizophrenia. *Am J Psychiatry*. 1996;153:355-361.
75. Lim KO, Zipursky RB, Murphy GM Jr, Pfefferbaum A. In vivo quantification of the limbic system using MRI: effects of normal aging. *Psychiatry Res*. 1990;35:15-26.
76. Peterson BS, Vohr B, Staib LH, Cannistraci CJ, Dolberg A, Schneider KC, Katz KH, Westerveld M, Sparrow S, Anderson AW, Duncan CC, Makuch RW, Gore JC, Ment LR. Regional brain volume abnormalities and long-term cognitive outcome in preterm infants. *JAMA*. 2000;284:1939-1947.
77. Rossi A, Stratta P, Mancini F, Gallucci M, Mattei P, Core L, Di Michele V, Casacchia M. Magnetic resonance imaging findings of amygdala-anterior hippocampus shrinkage in male patients with schizophrenia. *Psychiatry Res*. 1994;52:43-53.
78. Achten E, Deblaere K, De Wagter C, Van Damme F, Boon P, De Reuck J, Kunnen M. Intra- and interobserver variability of MRI-based volume measurements of the hippocampus and amygdala using the manual ray-tracing method. *Neuroradiology*. 1998;40:558-566.
79. Bartzokis G, Altshuler LL, Greider T, Curran J, Keen B, Dixon WJ. Reliability of medial temporal lobe volume measurements using reformatted 3D images. *Psychiatry Res*. 1998;82:11-24.
80. Bilir E, Craven W, Hugg J, Gilliam F, Martin R, Faught E, Kuzniecky R. Volumetric MRI of the limbic system: anatomic determinants. *Neuroradiology*. 1998;40:138-144.
81. Jack CR Jr. MRI-based hippocampal volume measurements in epilepsy. *Epilepsia*. 1994;35(suppl 6):S21-S29.
82. Kalviainen R, Salmenpera T, Partanen K, Vainio P, Riekkinen P Sr, Pitkanen A. MRI volumetry and T2 relaxometry of the amygdala in newly diagnosed and chronic temporal lobe epilepsy. *Epilepsy Res*. 1997;28:39-50.
83. Convit A, McHugh P, Wolf OT, de Leon MJ, Bobinski M, De Santi S, Roche A, Tsui W. MRI volume of the amygdala: a reliable method allowing separation from the hippocampal formation. *Psychiatry Res*. 1999;90:113-123.
84. Honeycutt NA, Smith PD, Aylward E, Li Q, Chan M, Barta PE, Pearlson GD. Mesial temporal lobe measurements on magnetic resonance imaging scans. *Psychiatry Res*. 1998;83:85-94.
85. Becker T, Elmer K, Schneider F, Schneider M, Grodd W, Bartels M, Heckers S, Beckmann H. Confirmation of reduced temporal limbic structure volume on magnetic resonance imaging in male patients with schizophrenia. *Psychiatry Res*. 1996;67:135-143.
86. Bernasconi N, Bernasconi A, Caramanos Z, Andermann F, Dubeau F, Arnold DL. Morphometric MRI analysis of the parahippocampal region in temporal lobe epilepsy. *Ann N Y Acad Sci*. 2000;911:495-500.
87. Cendes F, Leproux F, Melanson D, Ethier R, Evans A, Peters T, Andermann F. MRI of amygdala and hippocampus in temporal lobe epilepsy. *J Comput Assist Tomogr*. 1993;17:206-210.
88. Filipek PA, Semrud-Clikemen M, Steingard RJ, Renshaw PF, Kennedy DN, Beiderman J. Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. *Neurology*. 1997;48:589-601.
89. Free SL, Bergin PS, Fish DR, Cook MJ, Shorvon SD, Stevens JM. Methods for normalization of hippocampal volumes measured with MR. *AJNR Am J Neuroradiol*. 1995;16:637-643.
90. Altshuler LL, Conrad A, Hauser P, Li XM, Guze BH, Denicoff K, Tourtellotte W, Post R. Reduction of temporal lobe volume in bipolar disorder: a preliminary report of magnetic resonance imaging. *Arch Gen Psychiatry*. 1991;48:482-483.
91. Pfefferbaum A, Sullivan EV, Rosenbloom MJ, Mathalon DH, Lim KO. A controlled study of cortical gray matter and ventricular changes in alcoholic men over a 5-year interval. *Arch Gen Psychiatry*. 1998;55:905-912.
92. Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS, Blumenthal JD, James RS, Ebens CL, Walter JM, Zijdenbos A, Evans AC, Giedd JN, Rapoport JL. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. *JAMA*. 2002;288:1740-1748.
93. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. *J Clin Psychiatry*. 1999;60:733-740.
94. DelBello MP, Strakowski SM, Sax KW, McElroy SL, Keck PE Jr, West SA, Kmetz GF. Familial rates of affective and substance use disorders in patients with first-episode mania. *J Affect Disord*. 1999;56:55-60.